| Symbol
| CCL2
| contributors: mct/ - updated : 27-01-2017
|
| HGNC name
| chemokine (C-C motif) ligand 2
|
| HGNC id
| 10618
|
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| constitutional
|
|
| --over
|
| |
in chronic hepatite C virus infection and in amyotrophic lateral sclerosis progressing most rapidly | | constitutional
|
|
| --over
|
|
associated with chronic inflammation may contribute to the development of heart failure  | | tumoral
|
|
| --over
|
| |
clinical association of CCL2 overexpression in human cancers with poor prognosis | | tumoral
|
|
| --over
|
| |
CCL2 expression and macrophage infiltration are correlated with poor prognosis and metastatic disease in human breast cancer | | constitutional
|
|
| --over
|
| |
CCL2 and CCL3 are upregulated in the injured peripheral nerve through epigenetic histone modification in infiltrating immune cells such as macrophages | |
| Susceptibility
|
to severe chronic hepatite C virus infection (HCV) to pulmonary tuberculosis to idiopathic dilated cardiomyopathy (IDC) |
| Variant & Polymorphism
other
| associated with the susceptibility to RA |
|
2518 CCL2 G allele, may predispose HCV patients to more severe hepatic inflammation and fibrosis, and predisposing to severe pulmonary tuberculosis |
|
G allele at -2518 may be a novel genetic marker of susceptibility to nonfamilial IDC |
| 
|
Candidate gene
| Marker
| CCL2 and CCL3 are associated with progression of oral squamous cell carcinoma (OSCC) and may be potential biomarkers | Therapy target
|
|
| System | Type | Disorder | Pubmed |
|---|
| neuromuscular | neuropathy | | |
| attenuation of CCL2 upregulation by inhibition of ERK phosphorylation appears to be a most promising approach to treat a broader spectrum of inherited peripheral neuropathies | | diabete | | | |
| use of therapeutic strategies aimed at antagonizing CCL2 or IL6 signaling in diabetic kidney injury | | miscelleaneous | pain | | |
| antagonists of CCL2/CCR2 are promising agents from treating neuropathic pain. | | miscelleaneous | pain | | |
| targeting CCL2-CCR2 signaling may be a potentially important new treatment strategy for trigeminal neuralgia |
| | |
|
| Mcp1 -/- mice synthesized extremely low levels of interleukin-4, interleukin-5, and interleukin-10 | |
in Gjb1-deficient mice (Cx32def), Ccl2 is upregulated in a MEK–ERK-dependent manner (CCL2 reduction is a promising strategy to treat CMT1 neuropathies, particularly in disease forms where axon damage is predominant as in Cx32def mice and the corresponding human disorder, CMT1X) |
|
macrophages from Ccr2-null mice were not capable of promoting trans-endothelial migration of tumour cells |